Alnylam-discovered Livsayis wins FDA approval for generalized myasthenia gravis
REGN•
REGN•The FDA approved Livsayis (cemdisiran) for adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis. The approval triggers a $25 million payment from Regeneron to Alnylam, plus tiered double-digit royalties of up to 15% on global net sales.
The FDA approved Alnylam-discovered Livsayis (cemdisiran) for adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis. The approval triggers a $25 million payment from Regeneron to Alnylam, along with tiered, double-digit royalties of up to 15% on global net sales.
Regeneron will commercialize the treatment and assumed sole responsibility for its development, manufacturing and commercialization in 2024. Livsayis is the platform’s seventh FDA-approved therapy in less than nine years and the first RNAi treatment cleared for generalized myasthenia gravis.